AstraZeneca reviews data and announces vaccine is 76% effective

Published by Laurent P. · Published on 25 March 2021 at 14h19
As this Monday March 22, AstraZeneca laboratory stated their vaccine was 79% effective and show no risk of thromboses (blood clots), this Thursday March 25, the Swedish-British laboratory reviewed data as required by the NIAID (National Institute of Allergy and Infections Diseases), and announced updated data including vaccine was 76% effective.

Is AstraZeneca vaccine really safe? This is a question raised by many people so much divergent opinions are. How come? Cases of thrombosis reported a few days after being vaccinated with the solution, without a clear correlation between the two events, in about thirty people in Europe, that also led to the death of a thirty-year-old Norwegian nurse, a few days ago, halting vaccination campaigns in most European Union.

As the European Medicines Agency has granted the green light to resume vaccination a few days ago, after assessing cases reported, and despite the release of a Norwegian study showing the link between vaccine and blood clots, it is now the laboratory’s turn to reveal results – as of March 22 – of a new clinical trial led on the matter in the United States of America. Therefore, according to the laboratory, the vaccine is 79% effective and does not increase thrombosis risk. The vaccine is also 80% effective in people aged 65+, increasing their resistance to Covid.

Data called into question this Tuesday March 23 by the National Institute of Allergy and Infectious Diseases (NIAID), American regulator entrusted with the supervision of vaccines' clinical trials on the territory. The NIAID therefore explained in a release issued this Monday March 22 in the evening their "concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data".

They go on: "We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible".

Therefore, this March 25, new data have been provided and confirm the vaccine is 76% effective against asymptomatic cases. AstraZeneca also says in a release results "from the primary analysis of the Phase III trial of [the vaccine] in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis" as announced this Monday. Before adding the vaccine is 100% effective to prevent severe Covid. Yet, nothing about cases of thrombosis blamed by some for, even though correlation has not been established by health agencies.

For the record, as explained by Francetvinfo, Europeans are “more likely to see the vaccine as unsafe than safe”, according to a study issued this Monday by British survey institute YouGov, explaining the latter are more and more afraid of adverse effects. As a matter of fact, 61% of them think the vaccine is not safe, against 23% thinking it is. In Germany, 55% of the surveyed even consider the vaccine dangerous. Same think in Italy and Spain: 36% and 38% of the survey consider it is safe.

Practical information